Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
辉瑞(US:PFE) Businesswire·2026-01-10 23:00公司研发进展 - 辉瑞公司宣布其关键性BREAKWATER试验中独立随机队列Cohort 3的积极结果 [1] - 该试验评估BRAFTOVI® (encorafenib)联合西妥昔单抗(商品名ERBITUX®)及FOLFIRI方案用于治疗先前未经治疗的携带BRAF V600E突变的转移性结直肠癌患者 [1] 试验方案与适应症 - 试验方案为BRAFTOVI联合FOLFIRI和西妥昔单抗 [1] - 目标适应症为携带BRAF V600E突变的转移性结直肠癌 [1] - 患者群体为先前未经治疗的转移性结直肠癌患者 [1]